Stock Groups

Valneva targets 2022 revenue boost of up to 70% on COVID-19 vaccine -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – The logo for French-Austrian biotech company Valneva can be seen at their Vienna headquarters, Austria on December 16, 2021. REUTERS/Lisi Niesner

(Reuters] – French vaccine designer Valneva aims at increasing revenues by as much as 70% year over year thanks to a surge from COVID-19, the company announced on Thursday.

In 2022, the company expects to earn between 430 and 590 million euro ($485.73million to $666.46million), which includes 350 to 500 million Euros of COVID-19 vaccination sales. These are subject to regulatory approvals.

Valneva’s 2021 revenues soared 216% year on year to 348.1 millions euros. This was mainly because of COVID related revenue under a terminated arrangement in Britain.

($1 = 0.8853 euros)

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs are stocks, futures, indexes or Forex. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. Because prices might not reflect the market, they may be incorrect. This means that prices cannot be considered indicative and are inappropriate for trading. Fusion Media does not accept any liability for trade losses caused by the data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]